Breaking News

XOMA Acquires IXINITY Asset from Aptevo Therapeutics

XOMA gets the full commercial payment stream and a portion of Aptevo’s milestone rights for the Hemophilia B treatment.

XOMA has acquired the commercial payment and a portion of the milestone rights to IXINITY [coagulation factor IX (recombinant)], which is marketed by Medexus Pharmaceuticals for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B, from Aptevo Therapeutics. XOMA has acquired rights related to IXINITY for $9.6 million. “Adding a new commercial payment stream will benefit XOMA’s shareholders as we build our base of consistent incoming cash flo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters